| 摘要 |
Active agent combination (A) comprises at least one 3-phenyl-1-aza-spiro[4.5]dec-3-en-2-one compound (I), and one or more insecticidal and/or acaricidal compounds (II), preferably e.g. acetyl cholinesterase inhibitor (preferably alanycarb or aldicarb); (b) gamma -aminobutyric acid controlled chloride channel antagonists (preferably camphechlor or chlordane); (c) sodium channel-modulator/voltage-depe ndent sodium channel blocker (preferably acrinathrin, or bifenthrin); (d) nicotine acetylcholine-receptor-agonist/-antagonist (preferably acetamiprid or clothianidin). Active agent combination (A) comprises at least one 3-phenyl-1-aza-spiro[4.5]dec-3-en-2-one compound of formula (I), and one or more insecticidal and/or acaricidal compounds (II), preferably (a) acetyl cholinesterase inhibitor (which is: carbamate, preferably e.g. alanycarb, aldicarb, aldoxycarb, allyxycarb, aminocarb, bendiocarb, bufencarb, butacarb, carbaryl, carbofuran or carbosulfan, or organophosphate, e.g. preferably acephate, butathiofos, cadusafos, chlorethoxyfos, chlormephos, dialifos, diazinon, formothion or iprobenfos); (b) gamma -aminobutyric acid controlled chloride channel antagonists (e.g. organochlorine, camphechlor, chlordane, endosulfan, gamma -hexachlorocyclohexane, fiprole, acetoprole, ethiprole, fipronil, pyrafluprole, pyriprole or vaniliprole); (c) sodium channel-modulator/voltage-dependent sodium channel blocker (which is pyrethroide, preferably e.g. acrinathrin, beta -cyfluthrin, bifenthrin, bioallethrin, bioresmethrin, chlovaporthrin, clocythrin, cycloprothrin or tralomethrin); (d) nicotine acetylcholine-receptor-agonist/-antagonist (preferably e.g. acetamiprid, clothianidin, dinotefuran, imidacloprid, imidaclothiz, nitenpyram, nithiazine, thiacloprid or nicotine); (e) allosteric acetylcholine-receptor-modulator (agonist) (preferably spinosad or spinetoram); (f) chloride channel activator (which is mectine/macrolide, preferably abamectin, emamectin, emamectin-benzoate, ivermectin, lepimectin, milbemectin, juvenile hormone analogue, hydroprene, kinoprene, methoprene, epofenonane, triprene, fenoxycarb, pyriproxifen or diofenolan); (g) active agents with unknown or non-specific active mechanisms (which are: gassing agent (preferably methyl bromide, chloropicrin, sulfuryl fluoride), selective grub inhibitor (preferably cyrolite, pymetrozine or flonicamid) or mite growth inhibitor (preferably clofentezine, hexythiazox or etoxazole), inhibitors of oxidative phosphorylation, or ATP-disruptor (preferably diafenthiuron, organotin compounds (which are azocyclotin, cyhexatin or fenbutatin-oxide), propargite or tetradifon); (h) decoupler of the oxidative phoshorylation through interruption of the H-proton gradient (which is binapacryl, dinobuton or dinocap); (i) microbial disruptors of insect intestinal membrane (preferably Bacillus thuringiensisphyla), (j) inhibitors of chitin biosynthesis (preferably e.g. benzoylurea, bistrifluron, chlorfluazuron, diflubenzuron or buprofezin); (k) skin troubling active agents (preferably cyromazine), ecdyson agonist/disruptors (preferably e.g. diacylhydrazine, chromafenozide, halofenozide, tebufenozide or azadirachtin); (l) octopaminergic agonist (preferably amitraz); (m) side-III-electron transport inhibitor/side-II-electron transport inhibitor (preferably hydramethylnon, acequinocyl, fluacrypyrim, cyflumetofen or cyenopyrafen); (n) electron transport inhibitor (preferably side-I electron transport inhibitor, preferably e.g. fenazaquin, fenpyroximate, pyrimidifen, tolfenpyrad or rotenone)); (o) voltage dependent sodium channel blocker (preferably indoxacarb or metaflumizone); (p) fatty acid biosynthesis inhibitor, tetronic acid derivative (preferably spirodiclofen or spiromesifen), tetramic acid derivative (preferably spirotetramate); (q) neuronal inhibitor with unknown active mechanisms (preferably bifenazate); (r) ryanodin receptor effectors (preferably e.g. fluben diamide or rynaxapyr); and (s) active agents with unknown active mechanisms (preferably e.g. benclothiaz, benzoximate, bupr |
